JP6116539B2 - ポリペプチドを含有する生体内で多くの効果を有する医薬組成物及びその用途 - Google Patents
ポリペプチドを含有する生体内で多くの効果を有する医薬組成物及びその用途 Download PDFInfo
- Publication number
- JP6116539B2 JP6116539B2 JP2014245834A JP2014245834A JP6116539B2 JP 6116539 B2 JP6116539 B2 JP 6116539B2 JP 2014245834 A JP2014245834 A JP 2014245834A JP 2014245834 A JP2014245834 A JP 2014245834A JP 6116539 B2 JP6116539 B2 JP 6116539B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- polypeptide
- group
- mice
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 102
- 229920001184 polypeptide Polymers 0.000 title claims description 94
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 94
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 38
- 230000000694 effects Effects 0.000 title description 43
- 238000001727 in vivo Methods 0.000 title description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
- 201000010099 disease Diseases 0.000 claims description 24
- 108010057466 NF-kappa B Proteins 0.000 claims description 23
- 102000003945 NF-kappa B Human genes 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 16
- 206010012601 diabetes mellitus Diseases 0.000 claims description 13
- 206010061218 Inflammation Diseases 0.000 claims description 12
- 230000004054 inflammatory process Effects 0.000 claims description 12
- 210000004185 liver Anatomy 0.000 claims description 10
- 230000001105 regulatory effect Effects 0.000 claims description 10
- 201000000585 muscular atrophy Diseases 0.000 claims description 8
- 101150004675 Sirt1 gene Proteins 0.000 claims description 7
- 210000003734 kidney Anatomy 0.000 claims description 7
- 210000004072 lung Anatomy 0.000 claims description 5
- 102000040945 Transcription factor Human genes 0.000 claims description 4
- 108091023040 Transcription factor Proteins 0.000 claims description 4
- 210000000936 intestine Anatomy 0.000 claims description 4
- 208000004930 Fatty Liver Diseases 0.000 claims description 3
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 3
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 208000010706 fatty liver disease Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 3
- 206010067125 Liver injury Diseases 0.000 claims description 2
- 231100000234 hepatic damage Toxicity 0.000 claims description 2
- 230000008818 liver damage Effects 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- -1 Bcl3 Proteins 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 101100049203 Bacillus subtilis (strain 168) veg gene Proteins 0.000 claims 2
- 101150030450 IRS1 gene Proteins 0.000 claims 2
- 101710168942 Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 claims 2
- 102100030684 Sphingosine-1-phosphate phosphatase 1 Human genes 0.000 claims 2
- 101150073743 TNFRSF11B gene Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 101150077457 ACOX1 gene Proteins 0.000 claims 1
- 101150038502 ALDH2 gene Proteins 0.000 claims 1
- 101150048150 Acsl1 gene Proteins 0.000 claims 1
- 102100031786 Adiponectin Human genes 0.000 claims 1
- 101150052909 CCL2 gene Proteins 0.000 claims 1
- 101150112561 CD36 gene Proteins 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 101150029001 CDH2 gene Proteins 0.000 claims 1
- 101150051357 CYP17A1 gene Proteins 0.000 claims 1
- 101150100916 Casp3 gene Proteins 0.000 claims 1
- 101150073133 Cpt1a gene Proteins 0.000 claims 1
- 101100202237 Danio rerio rxrab gene Proteins 0.000 claims 1
- 101100309320 Danio rerio rxrga gene Proteins 0.000 claims 1
- 101000775469 Homo sapiens Adiponectin Proteins 0.000 claims 1
- 101150050263 ICAM1 gene Proteins 0.000 claims 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims 1
- 101150040099 MAP2K2 gene Proteins 0.000 claims 1
- 101150018665 MAPK3 gene Proteins 0.000 claims 1
- 101150031398 MAPK9 gene Proteins 0.000 claims 1
- 101150033138 MMP13 gene Proteins 0.000 claims 1
- 101150005607 Mdk gene Proteins 0.000 claims 1
- 101150106019 Mmp2 gene Proteins 0.000 claims 1
- 101100452374 Mus musculus Ikbke gene Proteins 0.000 claims 1
- 101100407078 Mus musculus Parp1 gene Proteins 0.000 claims 1
- 101150091206 Nfkbia gene Proteins 0.000 claims 1
- 101150044441 PECAM1 gene Proteins 0.000 claims 1
- 101150046396 PIK3R1 gene Proteins 0.000 claims 1
- 101150094555 PRKAG1 gene Proteins 0.000 claims 1
- 101150048674 PTPN11 gene Proteins 0.000 claims 1
- 102000037602 Platelet Endothelial Cell Adhesion Molecule-1 Human genes 0.000 claims 1
- 101150050070 RXRA gene Proteins 0.000 claims 1
- 101150076245 Rps6kb1 gene Proteins 0.000 claims 1
- 101150099493 STAT3 gene Proteins 0.000 claims 1
- 101150045565 Socs1 gene Proteins 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 101150045355 akt1 gene Proteins 0.000 claims 1
- 101150043789 cpt2 gene Proteins 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 101150096914 mttp gene Proteins 0.000 claims 1
- 101150005399 sod2 gene Proteins 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 85
- 150000001413 amino acids Chemical group 0.000 description 56
- 108090000623 proteins and genes Proteins 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 26
- 238000000034 method Methods 0.000 description 23
- 206010028980 Neoplasm Diseases 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 238000004020 luminiscence type Methods 0.000 description 17
- 201000011510 cancer Diseases 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 210000000056 organ Anatomy 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 230000037396 body weight Effects 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 239000002158 endotoxin Substances 0.000 description 12
- 238000003384 imaging method Methods 0.000 description 12
- 230000028709 inflammatory response Effects 0.000 description 12
- 229920006008 lipopolysaccharide Polymers 0.000 description 12
- 210000005228 liver tissue Anatomy 0.000 description 12
- 238000010186 staining Methods 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- 210000002700 urine Anatomy 0.000 description 10
- JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 9
- 102000000344 Sirtuin 1 Human genes 0.000 description 9
- 108010041191 Sirtuin 1 Proteins 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 235000009811 Momordica charantia Nutrition 0.000 description 7
- 244000078912 Trichosanthes cucumerina Species 0.000 description 7
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 238000011830 transgenic mouse model Methods 0.000 description 7
- 241000219104 Cucurbitaceae Species 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- 206010028289 Muscle atrophy Diseases 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 210000003855 cell nucleus Anatomy 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 239000007791 liquid phase Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 230000020763 muscle atrophy Effects 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 231100000915 pathological change Toxicity 0.000 description 6
- 230000036285 pathological change Effects 0.000 description 6
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 6
- 229960005079 pemetrexed Drugs 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 108010016731 PPAR gamma Proteins 0.000 description 5
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000007928 intraperitoneal injection Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000001308 synthesis method Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 241000796533 Arna Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000003859 lipid peroxidation Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- JVJFIQYAHPMBBX-FNORWQNLSA-N (E)-4-hydroxynon-2-enal Chemical compound CCCCCC(O)\C=C\C=O JVJFIQYAHPMBBX-FNORWQNLSA-N 0.000 description 3
- 238000000018 DNA microarray Methods 0.000 description 3
- 238000011771 FVB mouse Methods 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 description 3
- 102000008219 Uncoupling Protein 2 Human genes 0.000 description 3
- 108010021111 Uncoupling Protein 2 Proteins 0.000 description 3
- 241000021375 Xenogenes Species 0.000 description 3
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011503 in vivo imaging Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IZRSDCPUTJXPRQ-UHFFFAOYSA-N 4-hydroxynonanedioic acid Chemical compound OC(=O)CCC(O)CCCCC(O)=O IZRSDCPUTJXPRQ-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- 108010009306 Forkhead Box Protein O1 Proteins 0.000 description 2
- 102100035427 Forkhead box protein O1 Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000012355 Integrin beta1 Human genes 0.000 description 2
- 108010022222 Integrin beta1 Proteins 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000009739 binding Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000002803 maceration Methods 0.000 description 2
- 208000006178 malignant mesothelioma Diseases 0.000 description 2
- 201000005282 malignant pleural mesothelioma Diseases 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 229940016667 resveratrol Drugs 0.000 description 2
- 235000021283 resveratrol Nutrition 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000219195 Arabidopsis thaliana Species 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001131796 Botaurus stellaris Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000006311 Cyclin D1 Human genes 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 101001123331 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Proteins 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000219828 Medicago truncatula Species 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102100028960 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Human genes 0.000 description 1
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 108010001859 Proto-Oncogene Proteins c-rel Proteins 0.000 description 1
- 102000000850 Proto-Oncogene Proteins c-rel Human genes 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 240000006028 Sambucus nigra Species 0.000 description 1
- 235000003142 Sambucus nigra Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 240000003307 Zinnia violacea Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 235000008995 european elder Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000001890 gluconeogenic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000006444 vascular growth Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Botany (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Description
好ましくは、ポリペプチドのアミノ酸配列と配列番号SEQ ID No.1の配列は90%を超える類似度を有する。
好ましくは、ポリペプチドはマルチ遺伝子の調節剤(レギュレータ)であり、例えば、該マルチ遺伝子は少なくとも一つの特定な転写因子、例えばペルオキシソーム増殖因子活性化受容体、細胞核因子κB、Sirt1遺伝子あるいは前記2つ以上の遺伝子を含む。
好ましくは、該医薬組成物の用途は炎症または炎症反応を含む疾病を治療することに用いられる。
好ましくは、該医薬組成物の用途は代謝の症候群に関する疾病を治療することに用いられる。
好ましくは、該医薬組成物の用途は肥満症を治療することに用いられる。
好ましくは、該医薬組成物の用途は筋萎縮症を予防するまたは治療することに用いられる。
好ましくは、該医薬組成物の用途は、糖尿病の合併症の発生を低減することに用いられる。
該発明が属する技術分野における当業者としては、固相の合成法、組換え生物の製造プラットフォーム、あるいは/および植物の抽出方法などによりアミノ酸配列がSEQ ID No.1配列番号であるポリペプチドを製造できる。
本実施例の中で下記の材料を採用した。
(A)実験の対象:下記全ての動物試験はすでに中国医薬大学の動物保管および使用委員会の倫理委員会の同意が得られた。FVB系のマウスに対し実験を行い、これらのマウスは全て国家実験動物センター(National Laboratory Animal Center)から提供されたものである。
FVB系のマウスは対照グループと実験グループに均等に分けられ、実験グループのマウスの一匹ごとに対し下記ポリペプチドを2.5ミリモル/キロ体重(mmol/kg)含有するように、本発明の配列番号SEQ ID No.1のアミノ酸配列であるポリペプチドの溶液(20ミクロリットル)を投与し、7日継続して投与した。対照グループのマウスごとに20マイクロリットルのリン酸塩バッファーを投与した。試験が終わった後に、各該グループのマウスの空腸、筋肉、脂肪、肝臓、腎臓などの組織を取り出した後に、システム生物学を利用して多器官、マルチ標的の分析をを行った。本発明が属する技術分野の当業者が周知するDNAマイクロアレイにより、全ての遺伝子において調節される遺伝子の種類を観察でき、生物情報ソフトウェアをさらに利用して影響及び作用経路について分析できるため、さらにマイクロアレイと遺伝子発現マップによりメカニズムを研究することで、本発明のアミノ酸配列が配列番号SEQ ID No.1であるポリペプチドに影響された遺伝子を観察した。下記の通りに操作の流れについて詳細に説明する。
本実施例の中で、動物の生体内の発光イメージングの測定、動物の生体外の発光イメージングの測定、免疫組織の染色分析がそれぞれに対し効果の確認を行い、その中で、下記の材料を採用した。
(A)実験の対象:細胞核因子-κB (NF-κB)に調節されるルシフェラーゼ(Luciferase、luc)遺伝子導入されたマウスを野生型マウスF1と交配させ、FVB 遺伝特性を有するNF-κB/lucアロタイプ接合子の遺伝子導入マウスが産出されて、実験対象にした。
6〜8週間の雌性遺伝子導入された、合わせて15匹のマウスがランダムに均等に3つのグループに分けられ、その中で、第1グループはブランクグループであり、第2グループは対照グループであり、第3グループは実験グループである。腹腔内注射により、第2グループと第3グループの各該マウスに4ミリグラム/キロ体重のLPS(lipopolysaccharideを;LPS)炎症反応誘発剤を含む溶液(100ミクロリットル)を投与し、第1グループの各該マウスに100ミクロリットルのリン酸塩バッファーを投与した。5分間の後に、第3グループの各該マウスに0.5ミリグラム/キロ体重のポリペプチドを含む溶液20ミクロリットルを投与し、第1グループおよび第2グループの各該マウスに20ミクロリットルの水を投与した。4時間後に、それぞれin vivoイメージングで各該グループのマウスのルシフェラーゼの活性を観察した。
実施例3の(1)における各該グループのマウスに対し、まず、腹腔内注射により一匹ごとに150ミリグラム/キロ体重のルシフェリン(luciferin)を含有させ、5分間の後に、各該グループのマウスを犠牲にし、迅速にその脳、心臓、肺、肝臓、ひ臓、胃、腎臓、卵巣、腸を含む組織を取り出した。in vivoイメージングの設定は実施例3(1)の記載と同様であり、各該グループのマウスから取り出された器官それぞれがIVIS イメージングシステム200 シリーズ( IVIS Imaging System_ 200 Series 、Xenogen ,Hopkinton,MA)の撮影キャビンに置かれてイメージングを行い、生体イメージングソフトウェア(LivingImages softwareXenogen,Hopkinton,MA)により組織から発光した光量子の数を定量し、その結果を図5に示した。その中で、シグナルの強度の計算は組織から測定した光量子の総数であり、シグナルの強度の結果が毎秒の光量子の数(photons/sec)で示された。図5の結果に、各該グループのマウスの各臓器内の発光強度が異なり、その中で、卵巣以外は、対照グループのマウスの各該臓器から測定した発光強度がブランクグループのマウスに比べて、明らかに増加した。対照グループのマウスに比較して、実験グループのマウスの肺、肝臓、腎臓、腸などの臓器から測定した発光強度が明らかに低下したことが分かる。
表2の倍率の変化=第2グループの平均発光値/第1グループの平均発光値
表3の倍率の変化=第3グループの平均の発光値/第2グループの平均発光値
本発明に属する技術分野の当業者が知りうる周知技術により、各該グループのマウスから取り除いた器官に対しパラフィン包埋したを行った。パラフィン包埋した器官を5-μmのセクションにし、キシレンにより脱パラフィンを行い、次にGraded alcoholで脱水を行った後に、3%の過酸化水素の溶液ににより15分間で作用することで、内因性ペルオキシグーゼの活性を除去した後に、室温下で1%ウシ血清アルブミンにより1時間処理することで、非特異的結合を防止させた。その後、50倍で希釈された、p56、TNF-αまたはIL-1βに対するマウスモノクローナル抗体により4℃下で16-18時間処理し、翌日に、ビオチンを加えた(biotinylated)2次抗体(ZymedLaboratories、South San Francisco,CA)により室温下で20分間で処理した。最後に、各該スセクションが試薬avidin-biotin complexに置かれて、マニュアル(Histostain(r)-Plus Kit, Zymed Laboratories, South SanFrancisco,CA)手順に基づいて3,3'-ジアミノベンジジンにより染色を行って、その結果を図6に示した。
本実施例の中で下記の材料を採用した。
(A)実験対象:FVB系マウスを使用して実験を行い、これらのマウスは国家実験動物センター(National Laboratory Animal Center)から提供されたものである。
30匹のFVB系マウスはランダムに均等に3つグループに分けられ、その中で、第1グループがブランクグループである。第2グループが対照グループで、高脂肪飼料を食べさせた。第3グループが実験グループで、高脂肪飼料を食べさせ、かつ腹腔内注射により各該マウスに10ミリモル/キロ体重(mmol/kg)で本発明のアミノ酸配列のSEQ ID No.1配列番号1であるポリペプチドを含む溶液(100ミクロリットル)を週2回、4週間連続で投与し、第1グループおよび第2グループの各該マウスに対し100ミクロリットルのリン酸塩バッファーを投与した。
(A)本実施例で、下記の材料を採用した。実験の対象:遺伝子欠陥により腹部に脂肪が大量に堆積されたマウスを利用して実験を行った。これらのマウスすべては国家実験動物センター(National Laboratory Animal Center)から提供されたものである。
マウスを対照グループと実験グループに均等に分けて、腹腔内注射により、実験グループのマウス一匹ごとに2.5ナノモル/キロ体重(2.5 nmol/kg)を含有するように、本発明のアミノ酸配列の配列番号であるSEQ ID No.1 ポリペプチドの溶液(100ミクロリットル)を週2回、4週間連続で投与した。ブランクグループのマウスごとに対し100ミクロリットルのリン酸塩バッファーを投与した。
計算公式:(脂肪重量/体重)×100%,
その結果を下記の表4に示した。
本実施例で下記の材料を採用した。
(A)実験の対象:遺伝子欠陥により腹部に大量の脂肪が堆積されたマウスを利用して実験を行った。これらのマウスすべては国家実験動物センター(National Laboratory Animal Center)から提供されたものである。
実施例5の各該グループのマウスの筋肉組織を取り出した後に、本発明に属する技術分野の当業者が知りうる周知技術により、各該グループのマウスの筋肉組織に対しH&E染色を行い、その筋肉細胞の数及びサイズを観察し、その結果を図12に示した。
図12の結果から分かるように、対照グループのマウスが筋肉萎縮の症状を明らかに有し、本発明のポリペプチドを投与された実験グループのマウスの筋肉萎縮の状況を明らかに改善させた。それにより分かるように、本発明のアミノ酸配列の配列番号SEQ ID No.1であるポリペプチド1は確かに筋肉の合成に影響することができており、筋萎縮症に関する症状を予防・治療する効果を達成した。
本実施例で下記の材料を採用した。
(A)実験の対象:非肥満症性糖尿病のマウス(Non-obese diabetic mice、NOD mice)を使用してマウス実験を行った。これらのマウス全ては国家実験動物センター(National Laboratory Animal Center)から提供されたものである。
Claims (11)
- ポリペプチドを含み、多部位、マルチ遺伝子の調節用の医薬組成物であって、
前記ポリペプチドは、配列番号SEQ ID No.1の配列を含み、
前記多部位は、肌肉、脂肪、肺、肝、腎及び腸を含み、
前記マルチ遺伝子は、Ccl2、Icam1、Pecam1、Tnfrsf11b、Cdh2、Bcl3、Mapk3、Tnfrsf11b、ADIPOQ、Casp3、Ikbke、Irs1、Mapk9、Rxra、Ltf、Socs1、CD40、Mdk、Mmp13、Spp1、Vegfa、Cabin1、Igfbp5、Myh1、Irs1、Map2k2、Nfatc3、Adprt1、Pik3r1、Rps6kb1、Twist1、Akt1、Cd36、Acsl1、Nfkbia、Prkag1、Ptpn11、Stat3、Acox1、Cpt1a、Cpt2、Hsd17b4、Acsl4、Sirt1、Apoc3、Ctla4、Fabp2、Fgb、Hp、Mmp2、Aldh2、Ctla4、Cyp17a1、Mttp及びSod2を含む、
医薬組成物。 - 請求項1記載の医薬組成物において、
前記ポリペプチドのアミノ酸配列が配列番号SEQ ID No.1の配列である、
医薬組成物。 - 請求項1記載の医薬組成物において、
前記ポリペプチドのアミノ酸配列は配列番号SEQ ID No.1 の配列と90%を超える相同性(ホモロジー)を有する、
医薬組成物。 - 請求項1記載の医薬組成物において、
前記ポリペプチドは前記マルチ遺伝子の調節剤である、
医薬組成物。 - 請求項4記載の前記医薬組成物において、
前記マルチ遺伝子には少なくとも一つの特定の転写因子が含まれる、
医薬組成物。 - 請求項5項の医薬組成物において、
前記転写因子は、ペルオキシソーム増殖因子活性化受容体、細胞核因子κBおよびSirt1遺伝子からなる群より選択されたものである、
医薬組成物。 - 請求項1記載の医薬組成物を利用する、筋萎縮症の治療剤。
- 請求項1記載の医薬組成物を利用する、急性全身性炎症反応、肺、肝、腎、腸の炎症、或いはLPSによる炎症の治療剤。
- 請求項1記載の医薬組成物を利用する、脂肪肝又は肝臓の損傷による疾病の治療剤。
- 請求項1記載の医薬組成物を利用する、肥満症の治療剤。
- 請求項1記載の医薬組成物を利用する、糖尿病或いは糖尿病の合併症である眼疾患の低減剤。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW103129210A TWI580690B (zh) | 2014-08-25 | 2014-08-25 | The use of multidipins for the manufacture of pharmaceutical compositions for in vivo multipurpose effects |
TW103129210 | 2014-08-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016044172A JP2016044172A (ja) | 2016-04-04 |
JP6116539B2 true JP6116539B2 (ja) | 2017-04-19 |
Family
ID=53776294
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014245834A Active JP6116539B2 (ja) | 2014-08-25 | 2014-12-04 | ポリペプチドを含有する生体内で多くの効果を有する医薬組成物及びその用途 |
Country Status (8)
Country | Link |
---|---|
US (2) | US20160051620A1 (ja) |
EP (1) | EP2990050B1 (ja) |
JP (1) | JP6116539B2 (ja) |
KR (5) | KR20160024718A (ja) |
CN (1) | CN105363020A (ja) |
ES (1) | ES2745294T3 (ja) |
MY (1) | MY190709A (ja) |
TW (1) | TWI580690B (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112316109A (zh) * | 2020-12-02 | 2021-02-05 | 深圳市图微安创科技开发有限公司 | 多肽at03在治疗糖尿病肾病药物中的应用 |
TWI831072B (zh) * | 2021-11-04 | 2024-02-01 | 台北富邦商業銀行股份有限公司 | 開源軟體風險評鑑與智能監控系統及方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2219031T3 (da) * | 2001-10-22 | 2013-06-17 | Amgen Inc | Anvendelse af leptin til behandling af human lipoatrofi og fremgangsmåde til bestemmelse af prædisposition for behandlinngen |
CN100450552C (zh) * | 2006-05-26 | 2009-01-14 | 中国医学科学院医学生物学研究所 | Ⅰ型糖尿病疫苗及其构建方法 |
TWI360576B (en) | 2008-08-27 | 2012-03-21 | Taipei Veterans General Hospital | Pharmaceutically composition comprising resveratro |
TWI342781B (en) * | 2008-12-01 | 2011-06-01 | Univ China Medical | Blood sugar-modulating polypeptides |
TWI406668B (zh) | 2011-02-01 | 2013-09-01 | Univ Chaoyang Technology | 一種用於抑制幽門螺旋菌生長及抑制幽門螺旋菌誘導胃上皮細胞發炎反應之醫藥組合物 |
TW201300027A (zh) * | 2011-06-21 | 2013-01-01 | Univ Tunghai | 促肪解大豆胜肽之最適水解條件、序列及其應用 |
TWI588153B (zh) * | 2012-05-18 | 2017-06-21 | 中國醫藥大學 | 多胜肽、編碼該多胜肽之核酸分子、以及該多胜肽之應用 |
-
2014
- 2014-08-25 TW TW103129210A patent/TWI580690B/zh active
- 2014-09-22 CN CN201410487653.7A patent/CN105363020A/zh active Pending
- 2014-12-02 KR KR1020140170530A patent/KR20160024718A/ko not_active Application Discontinuation
- 2014-12-04 JP JP2014245834A patent/JP6116539B2/ja active Active
-
2015
- 2015-07-01 ES ES15174817T patent/ES2745294T3/es active Active
- 2015-07-01 EP EP15174817.5A patent/EP2990050B1/en active Active
- 2015-07-02 US US14/791,130 patent/US20160051620A1/en not_active Abandoned
- 2015-07-03 MY MYPI2015702193A patent/MY190709A/en unknown
-
2018
- 2018-02-19 US US15/898,989 patent/US20180369318A1/en not_active Abandoned
- 2018-03-06 KR KR1020180026283A patent/KR20180039589A/ko active Application Filing
-
2020
- 2020-09-25 KR KR1020200124802A patent/KR20200116073A/ko not_active Application Discontinuation
- 2020-09-25 KR KR1020200124806A patent/KR20200116074A/ko not_active Application Discontinuation
-
2021
- 2021-12-06 KR KR1020210173042A patent/KR20210153015A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20210153015A (ko) | 2021-12-16 |
CN105363020A (zh) | 2016-03-02 |
EP2990050B1 (en) | 2019-06-26 |
JP2016044172A (ja) | 2016-04-04 |
TW201607955A (zh) | 2016-03-01 |
US20160051620A1 (en) | 2016-02-25 |
MY190709A (en) | 2022-05-12 |
KR20200116074A (ko) | 2020-10-08 |
ES2745294T3 (es) | 2020-02-28 |
KR20180039589A (ko) | 2018-04-18 |
KR20200116073A (ko) | 2020-10-08 |
US20180369318A1 (en) | 2018-12-27 |
KR20160024718A (ko) | 2016-03-07 |
TWI580690B (zh) | 2017-05-01 |
EP2990050A1 (en) | 2016-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8697649B2 (en) | Polypeptides, nucleic acid molecule encoding polypeptides, and uses of polypeptides | |
KR20210153015A (ko) | 폴리펩티드를 함유한 생체 다중효과를 가진 약제학적 조성물 및 그 용도 | |
Terasaki et al. | Suppression of CC chemokine receptor 1 is a key regulation for colon cancer chemoprevention in AOM/DSS mice by fucoxanthin | |
JP2019533680A (ja) | 抗肥満および抗糖尿病効能を有するペプチド、並びにその用途 | |
Qiu et al. | Antihyperglycemic and antihyperlipidemic effects of low-molecular-weight carrageenan in rats | |
Kang et al. | Effects on goat meat extracts on α-glucosidase inhibitory activity, expression of Bcl-2-Associated X (BAX), p53, and p21 in cell line and expression of atrogin-1, Muscle Atrophy F-Box (MAFbx), Muscle RING-Finger Protein-1 (MuRF-1), and Myosin Heavy Chain-7 (MYH-7) in C2C12 myoblsts | |
US11723946B2 (en) | Methods for regulating transcription of multiple genes and expression of multiple targets | |
TWI593703B (zh) | Polypeptide for use in the manufacture of a pharmaceutical composition for the treatment or / and prevention of a disease associated with a target | |
Song et al. | MMP-12 siRNA improves the homeostasis of the small intestine and metabolic dysfunction in high-fat diet feeding-induced obese mice | |
CN110882286A (zh) | 去壁灵芝孢子粉的用途 | |
CN117448445B (zh) | Pten、tsc1和tsc2基因在马兜铃酸敏感性检测中的应用 | |
CN103239736B (zh) | 一种调节糖酵解和糖异生的方法和用途 | |
Zhu et al. | The Polysaccharide from Dendrobium officinale Can Improve Mice with Sjögren’s Syndrome by Regulating BAFF and Fas Expressions | |
WO2015041235A1 (ja) | 生活習慣病治療のための食品素材の使用 | |
Wu et al. | Phycocyanin-derived bioactive peptide PCP3 ameliorates lipopolysaccharide-induced small intestinal inflammation in murine intestinal organoids and mice through regulating Akt and AMPK/autophagy signaling | |
Pilśniak et al. | Gut microbiota and neoplastic diseases of the gastrointestinal tract | |
Chu et al. | Protective effects of Maillard products of skipjack trypsin hydrolysate on uric acid-induced injury of human kidney-2 cell (HK-2) | |
Xie et al. | Insights into the inhibition of stomach cancer MKN45 cell growth by Poria cocos ethanol-soluble extract based on MAPK/PI3K signaling pathways and components cell fishing | |
Jiang et al. | Qingre Jiangni formula improves esophageal epithelial barrier function in gastroesophageal reflux rats through male hormones and the p38/MAPK pathway | |
Zhuge et al. | Anti-breast cancer effect and mechanism of ethyl acetate extract of persimmon leaves | |
RU2601919C1 (ru) | Способ коррекции гепатотоксических реакций, индуцированных изониазидом | |
CN110327379A (zh) | 一种激活脂肪酸-g蛋白偶联受体通路的组合物 | |
CN111363821A (zh) | Ifi16作为抗肿瘤耐药增效及逆转的药物靶点的应用 | |
CN113476607A (zh) | Slc12a5及其抑制剂的应用 | |
CN110090254A (zh) | 一种用于肝保护和治疗肝纤维化的药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160113 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160628 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160926 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170228 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170321 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6116539 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |